<![CDATA[The Medical Brief]]>https://the-medical-brief-mwb6nj.jellypod.comPowered by Jellypod (https://www.jellypod.com)Sat, 17 Oct 2026 00:15:25 GMTTue, 14 Apr 2026 05:06:02 GMTyes60fc144a-a124-4170-b250-6d32151cebddThe Medical BriefEvidence-based medicine, made clear. Each week, The Medical Brief breaks down important studies, emerging treatments, diseases, and the science shaping modern healthcare. Clear context, careful explanations, and no sensationalism. For educational purposesEvidence-based medicine, made clear. Each week, The Medical Brief breaks down important studies, emerging treatments, diseases, and the science shaping modern healthcare. Clear context, careful explanations, and no sensationalism. For educational purposes only, not medical advice. Brought to you by Jellypod.serialThe Medical Brieffeed+0d145d45@podcasts.jellypod.comfalse<![CDATA[Beyond GLP-1: The Next Wave of Obesity Drugs]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/c1242a15-1b40-4625-bffe-7b878f0f1caec1242a15-1b40-4625-bffe-7b878f0f1caeTue, 14 Apr 2026 18:49:18 GMT11This episode explores how obesity treatment is moving from single-pathway GLP-1 drugs to dual and triple agonists like tirzepatide and retatrutide, with a look at the biology behind better weight-loss results. It also examines what the new data may mean for sleep apnea, cardiovascular risk, kidney disease, liver health, and the practical limits of long-term use, side effects, and access.

]]>The Medical BriefThis episode explores how obesity treatment is moving from single-pathway GLP-1 drugs to dual and triple agonists like tirzepatide and retatrutide, with a look at the biology behind better weight-loss results. It also examines what the new data may mean fThis episode explores how obesity treatment is moving from single-pathway GLP-1 drugs to dual and triple agonists like tirzepatide and retatrutide, with a look at the biology behind better weight-loss results. It also examines what the new data may mean for sleep apnea, cardiovascular risk, kidney disease, liver health, and the practical limits of long-term use, side effects, and access.false00:08:55full<![CDATA[Aspirin After Joint Replacement: The EPCAT III Shift]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/d42bdaf1-5d91-4152-bfc7-4bc1e77c5bb8d42bdaf1-5d91-4152-bfc7-4bc1e77c5bb8Sat, 18 Jul 2026 14:33:55 GMT22A deep dive into why blood clots are a risk after hip and knee replacement, and how modern care has driven rates so low. The hosts unpack the EPCAT III trial, showing aspirin can be noninferior to rivaroxaban for many routine patients while also reducing cost and discharge headaches.

]]>The Medical BriefA deep dive into why blood clots are a risk after hip and knee replacement, and how modern care has driven rates so low. The hosts unpack the EPCAT III trial, showing aspirin can be noninferior to rivaroxaban for many routine patients while also reducing A deep dive into why blood clots are a risk after hip and knee replacement, and how modern care has driven rates so low. The hosts unpack the EPCAT III trial, showing aspirin can be noninferior to rivaroxaban for many routine patients while also reducing cost and discharge headaches.false00:06:48full<![CDATA[Oxygen After Cardiac Arrest: What the LOGICAL Trial Found]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/0aa0f3af-8350-47d7-bf42-78e145f2fb7f0aa0f3af-8350-47d7-bf42-78e145f2fb7fSun, 19 Jul 2026 14:33:57 GMT33We unpack the biological case against hyperoxia after cardiac arrest, then examine the large LOGICAL trial and its surprising finding: tightly restricting oxygen did not improve six-month neurological recovery compared with a more liberal approach.

]]>The Medical BriefWe unpack the biological case against hyperoxia after cardiac arrest, then examine the large LOGICAL trial and its surprising finding: tightly restricting oxygen did not improve six-month neurological recovery compared with a more liberal approach.We unpack the biological case against hyperoxia after cardiac arrest, then examine the large LOGICAL trial and its surprising finding: tightly restricting oxygen did not improve six-month neurological recovery compared with a more liberal approach.false00:07:32full<![CDATA[Gene Silencing vs Stabilization in ATTR Cardiomyopathy]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/7e1abe2f-a31d-46e9-bf3d-2a2ba46d84277e1abe2f-a31d-46e9-bf3d-2a2ba46d8427Mon, 20 Jul 2026 14:34:25 GMT44This episode breaks down how transthyretin misfolding drives ATTR cardiomyopathy, comparing tafamidis stabilization with vutrisiran’s RNAi gene-silencing approach. The hosts also unpack HELIOS-B results, functional outcomes, and the real-world challenge of whether costly combination therapy is worth it.

Show Notes

]]>The Medical BriefThis episode breaks down how transthyretin misfolding drives ATTR cardiomyopathy, comparing tafamidis stabilization with vutrisiran’s RNAi gene-silencing approach. The hosts also unpack HELIOS-B results, functional outcomes, and the real-world challenge oThis episode breaks down how transthyretin misfolding drives ATTR cardiomyopathy, comparing tafamidis stabilization with vutrisiran’s RNAi gene-silencing approach. The hosts also unpack HELIOS-B results, functional outcomes, and the real-world challenge of whether costly combination therapy is worth it. Show Notes Vutrisiran in Patients with Transthyretin Amyloidosis ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134 Contextualizing the results of HELIOS-B in the broader ... - PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11805581/ Alnylam Announces FDA Approval of AMVUTTRA ...: https://investors.alnylam.com/press-release?id=28831false00:06:35full<![CDATA[Are Beta-Blockers Still Needed After a Heart Attack?]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/fec36fd3-2e39-44bf-b4d5-39b06e15dfb8fec36fd3-2e39-44bf-b4d5-39b06e15dfb8Tue, 21 Jul 2026 14:34:59 GMT55A deep dive into the REDUCE-AMI trial and what it means for patients recovering from a heart attack with preserved ejection fraction. The hosts examine why beta-blockers may no longer provide the same benefit in the modern PCI era, and where deprescribing fits in without abandoning patients who still need the drug.

Show Notes

]]>The Medical BriefA deep dive into the REDUCE-AMI trial and what it means for patients recovering from a heart attack with preserved ejection fraction. The hosts examine why beta-blockers may no longer provide the same benefit in the modern PCI era, and where deprescribingA deep dive into the REDUCE-AMI trial and what it means for patients recovering from a heart attack with preserved ejection fraction. The hosts examine why beta-blockers may no longer provide the same benefit in the modern PCI era, and where deprescribing fits in without abandoning patients who still need the drug. Show Notes Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute ...: https://www.tctmd.com/news/another-beta-blocker-blow-reduce-ami-confirms-no-benefit-after-acute-mifalse00:06:29full<![CDATA[Teclistamab in Early Myeloma Relapse: Promise and Peril]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/ce0b9c25-cfac-4bd7-9001-76d3ecb445ccce0b9c25-cfac-4bd7-9001-76d3ecb445ccWed, 22 Jul 2026 14:35:31 GMT66This episode explores how earlier relapse in multiple myeloma is creating a tougher treatment landscape, especially for patients already resistant to lenalidomide and anti-CD38 therapy. The hosts break down MajesTEC-9, where teclistamab delivered major efficacy gains but also brought significant infection risk, CRS, and new logistical challenges for early-relapse care.

]]>The Medical BriefThis episode explores how earlier relapse in multiple myeloma is creating a tougher treatment landscape, especially for patients already resistant to lenalidomide and anti-CD38 therapy. The hosts break down MajesTEC-9, where teclistamab delivered major efThis episode explores how earlier relapse in multiple myeloma is creating a tougher treatment landscape, especially for patients already resistant to lenalidomide and anti-CD38 therapy. The hosts break down MajesTEC-9, where teclistamab delivered major efficacy gains but also brought significant infection risk, CRS, and new logistical challenges for early-relapse care.false00:06:35full<![CDATA[PCSK9 Inhibitors in Primary Prevention]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/a63a6bde-a134-408a-852f-f180fa31449da63a6bde-a134-408a-852f-f180fa31449dThu, 23 Jul 2026 14:37:50 GMT77We break down how PCSK9 inhibition with evolocumab can sharply lower LDL and reduce first-time cardiovascular events in high-risk patients who have never had a heart attack or stroke. The episode also weighs the real-world tradeoffs: absolute risk reduction, NNT, cost, and the limits of applying trial results to more diverse populations.

]]>The Medical BriefWe break down how PCSK9 inhibition with evolocumab can sharply lower LDL and reduce first-time cardiovascular events in high-risk patients who have never had a heart attack or stroke. The episode also weighs the real-world tradeoffs: absolute risk reductiWe break down how PCSK9 inhibition with evolocumab can sharply lower LDL and reduce first-time cardiovascular events in high-risk patients who have never had a heart attack or stroke. The episode also weighs the real-world tradeoffs: absolute risk reduction, NNT, cost, and the limits of applying trial results to more diverse populations.false00:08:04full<![CDATA[CHAMPION-AF: Can a Heart Device Replace Blood Thinners?]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/568bc53b-b688-43b6-afa7-e920cdbc511f568bc53b-b688-43b6-afa7-e920cdbc511fFri, 24 Jul 2026 14:36:24 GMT88This episode breaks down the CHAMPION-AF trial, where left atrial appendage closure was tested against DOACs in typical atrial fibrillation patients who were eligible for either treatment. The hosts explore why the device lowered long-term bleeding but came with procedural tradeoffs and a slightly higher numerical stroke rate.

Show Notes

]]>The Medical BriefThis episode breaks down the CHAMPION-AF trial, where left atrial appendage closure was tested against DOACs in typical atrial fibrillation patients who were eligible for either treatment. The hosts explore why the device lowered long-term bleeding but caThis episode breaks down the CHAMPION-AF trial, where left atrial appendage closure was tested against DOACs in typical atrial fibrillation patients who were eligible for either treatment. The hosts explore why the device lowered long-term bleeding but came with procedural tradeoffs and a slightly higher numerical stroke rate. Show Notes CHAMPION-AF: Left Atrial Appendage Closure vs. ...: https://www.acc.org/latest-in-cardiology/articles/2026/03/25/21/27/sat-930am-championaf-acc-2026false00:08:14full<![CDATA[Valproate, Paternal Risk, and the Confounding Mirage]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/4b42cb3a-0369-4667-b7d2-35d23843bfcb4b42cb3a-0369-4667-b7d2-35d23843bfcbSat, 25 Jul 2026 14:34:10 GMT99A look at the 2024 paternal valproate warning, the biology behind the 90-day spermatogenesis window, and how early registry signals sparked major counseling dilemmas for men with epilepsy or bipolar disorder.

The episode then unpacks a large 2026 study showing the apparent risk largely disappeared after controlling for confounding by indication, offering reassurance for clinical decision-making.

]]>The Medical BriefA look at the 2024 paternal valproate warning, the biology behind the 90-day spermatogenesis window, and how early registry signals sparked major counseling dilemmas for men with epilepsy or bipolar disorder. The episode then unpacks a large 2026 study shA look at the 2024 paternal valproate warning, the biology behind the 90-day spermatogenesis window, and how early registry signals sparked major counseling dilemmas for men with epilepsy or bipolar disorder. The episode then unpacks a large 2026 study showing the apparent risk largely disappeared after controlling for confounding by indication, offering reassurance for clinical decision-making.false00:05:42full<![CDATA[Why Delaying STEMI Reperfusion Fell Flat]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/c8cd7227-0a45-4840-9b61-ef1a52b26a72c8cd7227-0a45-4840-9b61-ef1a52b26a72Sun, 26 Jul 2026 14:34:21 GMT1010This episode explores the paradox of ischemic reperfusion injury in acute STEMI and the theory behind pre-reperfusion ventricular unloading with Impella CP. The hosts break down the STEMI DTU trial, showing why a deliberate 30-minute delay failed to reduce infarct size and dramatically increased bleeding and vascular complications.

]]>The Medical BriefThis episode explores the paradox of ischemic reperfusion injury in acute STEMI and the theory behind pre-reperfusion ventricular unloading with Impella CP. The hosts break down the STEMI DTU trial, showing why a deliberate 30-minute delay failed to reducThis episode explores the paradox of ischemic reperfusion injury in acute STEMI and the theory behind pre-reperfusion ventricular unloading with Impella CP. The hosts break down the STEMI DTU trial, showing why a deliberate 30-minute delay failed to reduce infarct size and dramatically increased bleeding and vascular complications.false00:06:31full<![CDATA[Magnetic Shunt Trial Solves a 60-Year NPH Mystery]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/e434070b-dee1-4cc7-a8fc-d382cd32569be434070b-dee1-4cc7-a8fc-d382cd32569bMon, 27 Jul 2026 14:35:11 GMT1111An in-depth look at how researchers finally tested shunt surgery for idiopathic normal pressure hydrocephalus without sham operations, using a magnetic valve to compare active drainage against placebo. The findings reveal a major boost in walking and balance, but little short-term benefit for cognition or bladder symptoms, along with the risks of overdrainage.

]]>The Medical BriefAn in-depth look at how researchers finally tested shunt surgery for idiopathic normal pressure hydrocephalus without sham operations, using a magnetic valve to compare active drainage against placebo. The findings reveal a major boost in walking and balaAn in-depth look at how researchers finally tested shunt surgery for idiopathic normal pressure hydrocephalus without sham operations, using a magnetic valve to compare active drainage against placebo. The findings reveal a major boost in walking and balance, but little short-term benefit for cognition or bladder symptoms, along with the risks of overdrainage.false00:08:20full<![CDATA[When Cross-Protection Fails: The GoGoVax Reality Check]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/b74984c0-42aa-40b2-b4c2-75582e1cedceb74984c0-42aa-40b2-b4c2-75582e1cedceTue, 28 Jul 2026 14:34:56 GMT1212A deep dive into why a promising meningitis B vaccine appeared to reduce gonorrhea in observational studies, only for a randomized trial to show the protection vanished. The hosts unpack cross-protection, mucosal immunity, and the confounding factors that can make a public health breakthrough look far more real than it is.

]]>The Medical BriefA deep dive into why a promising meningitis B vaccine appeared to reduce gonorrhea in observational studies, only for a randomized trial to show the protection vanished. The hosts unpack cross-protection, mucosal immunity, and the confounding factors thatA deep dive into why a promising meningitis B vaccine appeared to reduce gonorrhea in observational studies, only for a randomized trial to show the protection vanished. The hosts unpack cross-protection, mucosal immunity, and the confounding factors that can make a public health breakthrough look far more real than it is.false00:05:20full<![CDATA[YEARS in Cancer Patients: What the Hydra Trial Really Means]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/2ebb1c88-3386-4840-ac50-a9eb20979f242ebb1c88-3386-4840-ac50-a9eb20979f24Wed, 29 Jul 2026 14:38:10 GMT1313A deep dive into why suspected pulmonary embolism is so hard to manage in patients with active cancer, from the risks of routine CT scanning to the promise of the YEARS diagnostic pathway. The episode also unpacks the Hydra trial and the Bayesian logic behind why a rule-out strategy that works in the general population may still leave a meaningful residual risk in oncology patients.

]]>The Medical BriefA deep dive into why suspected pulmonary embolism is so hard to manage in patients with active cancer, from the risks of routine CT scanning to the promise of the YEARS diagnostic pathway. The episode also unpacks the Hydra trial and the Bayesian logic beA deep dive into why suspected pulmonary embolism is so hard to manage in patients with active cancer, from the risks of routine CT scanning to the promise of the YEARS diagnostic pathway. The episode also unpacks the Hydra trial and the Bayesian logic behind why a rule-out strategy that works in the general population may still leave a meaningful residual risk in oncology patients.false00:07:14full<![CDATA[Once-Weekly HIV Therapy: A New Era for Adherence]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/78d3135b-1286-44f4-96dd-0cf54b2f17a578d3135b-1286-44f4-96dd-0cf54b2f17a5Thu, 30 Jul 2026 14:36:05 GMT1414An in-depth look at a new once-weekly HIV treatment strategy that matched daily therapy in a head-to-head trial, with discussion of adherence fatigue, viral suppression, and the importance of diverse clinical data.

The episode also explores the pharmacology behind islatravir and lenacapavir, plus the safety concerns that nearly derailed islatravir before researchers found a lower-dose path forward.

]]>The Medical BriefAn in-depth look at a new once-weekly HIV treatment strategy that matched daily therapy in a head-to-head trial, with discussion of adherence fatigue, viral suppression, and the importance of diverse clinical data. The episode also explores the pharmacoloAn in-depth look at a new once-weekly HIV treatment strategy that matched daily therapy in a head-to-head trial, with discussion of adherence fatigue, viral suppression, and the importance of diverse clinical data. The episode also explores the pharmacology behind islatravir and lenacapavir, plus the safety concerns that nearly derailed islatravir before researchers found a lower-dose path forward.false00:07:29full<![CDATA[Finerenone’s New Role in HFpEF and HFmrEF]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/4b758f16-699b-48fe-93d0-92cb49aa3bba4b758f16-699b-48fe-93d0-92cb49aa3bbaFri, 31 Jul 2026 14:34:07 GMT1515This episode breaks down how finerenone is changing care for patients with preserved or mildly reduced ejection fraction heart failure, moving beyond the limitations of spironolactone and other steroidal MRAs. The hosts review the FINEARTS HF trial results, including fewer worsening heart failure events, the lack of a clear mortality benefit, and the real-world need to monitor potassium and kidney function closely.

Show Notes

]]>The Medical BriefThis episode breaks down how finerenone is changing care for patients with preserved or mildly reduced ejection fraction heart failure, moving beyond the limitations of spironolactone and other steroidal MRAs. The hosts review the FINEARTS HF trial resultThis episode breaks down how finerenone is changing care for patients with preserved or mildly reduced ejection fraction heart failure, moving beyond the limitations of spironolactone and other steroidal MRAs. The hosts review the FINEARTS HF trial results, including fewer worsening heart failure events, the lack of a clear mortality benefit, and the real-world need to monitor potassium and kidney function closely. Show Notes Finerenone in Heart Failure with Mildly Reduced or ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107false00:06:17full<![CDATA[Baxdrostat and the New Frontier in Resistant Hypertension]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/127f8627-0d5b-4061-9c62-a7f115f80d2f127f8627-0d5b-4061-9c62-a7f115f80d2fSat, 01 Aug 2026 14:34:02 GMT1616We break down why resistant hypertension can be so hard to control, and how aldosterone drives sodium retention, vascular stiffening, and persistent high blood pressure. The episode also examines the BaxHTN trial of baxdrostat, including its blood pressure benefits, the risk of hyperkalemia, and what still needs to be proven about long-term outcomes.

Show Notes

]]>The Medical BriefWe break down why resistant hypertension can be so hard to control, and how aldosterone drives sodium retention, vascular stiffening, and persistent high blood pressure. The episode also examines the BaxHTN trial of baxdrostat, including its blood pressurWe break down why resistant hypertension can be so hard to control, and how aldosterone drives sodium retention, vascular stiffening, and persistent high blood pressure. The episode also examines the BaxHTN trial of baxdrostat, including its blood pressure benefits, the risk of hyperkalemia, and what still needs to be proven about long-term outcomes. Show Notes Efficacy and Safety of Baxdrostat in Uncontrolled and ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2507109false00:06:26full<![CDATA[CREST 2 and the Asymptomatic Carotid Dilemma]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/22ed36a6-4feb-428c-ba16-e74fd9a77d1f22ed36a6-4feb-428c-ba16-e74fd9a77d1fSun, 02 Aug 2026 14:34:09 GMT1717This episode breaks down the CREST 2 trials and the tough decision facing patients with severe asymptomatic carotid stenosis: accept the upfront risk of stenting or surgery, or rely on intensive medical therapy alone. The hosts examine short-term procedural harms, four-year outcomes, and why modern medication has changed the standard of care.

Show Notes

]]>The Medical BriefThis episode breaks down the CREST 2 trials and the tough decision facing patients with severe asymptomatic carotid stenosis: accept the upfront risk of stenting or surgery, or rely on intensive medical therapy alone. The hosts examine short-term procedurThis episode breaks down the CREST 2 trials and the tough decision facing patients with severe asymptomatic carotid stenosis: accept the upfront risk of stenting or surgery, or rely on intensive medical therapy alone. The hosts examine short-term procedural harms, four-year outcomes, and why modern medication has changed the standard of care. Show Notes Medical Management and Revascularization for ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2508800false00:05:26full<![CDATA[Iptacopan in IgA Nephropathy: Slowing Kidney Failure]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/bb3c386f-9c86-4669-9be7-6d03d22240debb3c386f-9c86-4669-9be7-6d03d22240deMon, 03 Aug 2026 14:34:43 GMT1818This episode breaks down the APPLAUSE IgAN phase 3 trial of iptacopan in high-risk IgA nephropathy, highlighting meaningful slowing of eGFR decline, lower kidney failure events, and how surrogate proteinuria changes translated into real clinical benefit.

It also examines the trade-off of complement blockade, including the need for careful vaccination and the increased risk of serious infections in patients with severe proteinuria.

Show Notes

]]>The Medical BriefThis episode breaks down the APPLAUSE IgAN phase 3 trial of iptacopan in high-risk IgA nephropathy, highlighting meaningful slowing of eGFR decline, lower kidney failure events, and how surrogate proteinuria changes translated into real clinical benefit. This episode breaks down the APPLAUSE IgAN phase 3 trial of iptacopan in high-risk IgA nephropathy, highlighting meaningful slowing of eGFR decline, lower kidney failure events, and how surrogate proteinuria changes translated into real clinical benefit. It also examines the trade-off of complement blockade, including the need for careful vaccination and the increased risk of serious infections in patients with severe proteinuria. Show Notes Iptacopan Slows Kidney Function Decline in IgA Nephropathy: https://www.renalandurologynews.com/news/iga-neprhopathy-iptacopan-kidney-function-treatment-risk/ Iptacopan for IgA Nephropathy in: https://www.kidneynews.org/view/journals/kidney-news/18/5/article-p29_19.xmlfalse00:05:54full<![CDATA[Fixed-Duration Therapy Challenges Continuous CLL Treatment]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/b283bf04-f97e-418c-95af-4181b70e2824b283bf04-f97e-418c-95af-4181b70e2824Tue, 04 Aug 2026 14:33:42 GMT1919A deep dive into the CLL17 trial and the shift from indefinite BTK inhibition to fixed-duration venetoclax-based therapy. The hosts unpack noninferior progression-free survival, striking MRD clearance, and the trade-offs between continuous treatment and a defined endpoint.

Show Notes

]]>The Medical BriefA deep dive into the CLL17 trial and the shift from indefinite BTK inhibition to fixed-duration venetoclax-based therapy. The hosts unpack noninferior progression-free survival, striking MRD clearance, and the trade-offs between continuous treatment and aA deep dive into the CLL17 trial and the shift from indefinite BTK inhibition to fixed-duration venetoclax-based therapy. The hosts unpack noninferior progression-free survival, striking MRD clearance, and the trade-offs between continuous treatment and a defined endpoint. Show Notes Fixed-Duration versus Continuous Treatment for Chronic ...: https://www.nejm.org/doi/full/10.1056/NEJMoa2515458false00:05:51full<![CDATA[EARLY TAVR and the Asymptomatic Paradox]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/fc7ddcce-3c8e-46f9-adc5-701b0577f9f2fc7ddcce-3c8e-46f9-adc5-701b0577f9f2Wed, 05 Aug 2026 14:34:24 GMT2020This episode examines the EARLY TAVR trial and why “asymptomatic” severe aortic stenosis may be misleading, with treadmill testing revealing many patients were not truly symptom-free. It also breaks down the results: fewer unplanned hospitalizations with early intervention, but no clear mortality benefit yet, alongside the procedural risks and shared decision-making implications.

]]>The Medical BriefThis episode examines the EARLY TAVR trial and why “asymptomatic” severe aortic stenosis may be misleading, with treadmill testing revealing many patients were not truly symptom-free. It also breaks down the results: fewer unplanned hospitalizations with This episode examines the EARLY TAVR trial and why “asymptomatic” severe aortic stenosis may be misleading, with treadmill testing revealing many patients were not truly symptom-free. It also breaks down the results: fewer unplanned hospitalizations with early intervention, but no clear mortality benefit yet, alongside the procedural risks and shared decision-making implications.false00:05:46full<![CDATA[Do Shock Patients Need an Arterial Line Right Away?]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/f98c0a15-d4b7-49de-b3b7-65c173d6e7eef98c0a15-d4b7-49de-b3b7-65c173d6e7eeThu, 06 Aug 2026 14:34:02 GMT2121We break down the EVERDAC trial, a multicenter randomized study asking whether critically ill patients with shock really need an immediate arterial line. The episode covers noninferior mortality outcomes, major reductions in catheter-related bleeding, and how this could shift ICU practice toward a more selective, noninvasive approach.

Show Notes

]]>The Medical BriefWe break down the EVERDAC trial, a multicenter randomized study asking whether critically ill patients with shock really need an immediate arterial line. The episode covers noninferior mortality outcomes, major reductions in catheter-related bleeding, andWe break down the EVERDAC trial, a multicenter randomized study asking whether critically ill patients with shock really need an immediate arterial line. The episode covers noninferior mortality outcomes, major reductions in catheter-related bleeding, and how this could shift ICU practice toward a more selective, noninvasive approach. Show Notes Deferring Arterial Catheterization in Critically Ill Patients with Shock | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2502136false00:05:58full<![CDATA[Bicarbonate in Shock: Why Fixing the pH Isn’t Enough]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/fa13f9c2-639e-4d6e-9b0f-357f8bf1fddffa13f9c2-639e-4d6e-9b0f-357f8bf1fddfFri, 07 Aug 2026 14:33:09 GMT2222A critical care discussion of why sodium bicarbonate often looks helpful on the blood gas but fails to improve outcomes in vasopressor-dependent metabolic acidosis. The episode breaks down the SODa BIC trial, the surrogate endpoint trap, and when bicarbonate may still have a role in select ICU patients.

]]>The Medical BriefA critical care discussion of why sodium bicarbonate often looks helpful on the blood gas but fails to improve outcomes in vasopressor-dependent metabolic acidosis. The episode breaks down the SODa BIC trial, the surrogate endpoint trap, and when bicarbonA critical care discussion of why sodium bicarbonate often looks helpful on the blood gas but fails to improve outcomes in vasopressor-dependent metabolic acidosis. The episode breaks down the SODa BIC trial, the surrogate endpoint trap, and when bicarbonate may still have a role in select ICU patients.false00:06:14full<![CDATA[C-TRACT Trial: Stenting Gains, Bleeding Costs]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/f2b37cf4-22f7-4c0f-b49f-cdb944c0c6d7f2b37cf4-22f7-4c0f-b49f-cdb944c0c6d7Sat, 08 Aug 2026 14:33:08 GMT2323This episode breaks down the C-TRACT trial, comparing iliac vein stenting with standard care for post-thrombotic syndrome and highlighting the trial’s strong improvements in symptoms and quality of life.

It also weighs the trade-offs: higher bleeding risk, heavier antithrombotic therapy, and the unresolved questions around long-term stent durability.

]]>The Medical BriefThis episode breaks down the C-TRACT trial, comparing iliac vein stenting with standard care for post-thrombotic syndrome and highlighting the trial’s strong improvements in symptoms and quality of life. It also weighs the trade-offs: higher bleeding riskThis episode breaks down the C-TRACT trial, comparing iliac vein stenting with standard care for post-thrombotic syndrome and highlighting the trial’s strong improvements in symptoms and quality of life. It also weighs the trade-offs: higher bleeding risk, heavier antithrombotic therapy, and the unresolved questions around long-term stent durability.false00:05:16full<![CDATA[Finerenone in Non-Diabetic CKD: FIND-CKD Explained]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/95719157-4231-4e73-9ac5-177a64dafe2395719157-4231-4e73-9ac5-177a64dafe23Sun, 09 Aug 2026 14:34:26 GMT2424We break down the FIND-CKD trial and what it means for people with non-diabetic chronic kidney disease and proteinuria, focusing on finerenone’s impact on eGFR decline, kidney-related outcomes, and why an early dip in kidney function may not be a warning sign.

The episode also covers hyperkalemia risk, practical dose adjustment strategies, and the big question of how finerenone fits alongside ACE inhibitors, ARBs, and SGLT2 inhibitors in modern kidney care.

]]>The Medical BriefWe break down the FIND-CKD trial and what it means for people with non-diabetic chronic kidney disease and proteinuria, focusing on finerenone’s impact on eGFR decline, kidney-related outcomes, and why an early dip in kidney function may not be a warning We break down the FIND-CKD trial and what it means for people with non-diabetic chronic kidney disease and proteinuria, focusing on finerenone’s impact on eGFR decline, kidney-related outcomes, and why an early dip in kidney function may not be a warning sign. The episode also covers hyperkalemia risk, practical dose adjustment strategies, and the big question of how finerenone fits alongside ACE inhibitors, ARBs, and SGLT2 inhibitors in modern kidney care.false00:07:14full<![CDATA[KarXT and the End of Dopamine-Only Schizophrenia Treatment]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/8d7b1b28-4c6a-4e41-b2b7-51c22fd947cd8d7b1b28-4c6a-4e41-b2b7-51c22fd947cdMon, 10 Aug 2026 14:32:58 GMT2525This episode explores a new mechanistic approach to treating schizophrenia with xanomeline-trospium, which targets central muscarinic receptors to reduce psychosis without directly blocking dopamine. It also breaks down the EMERGENT trial results, including efficacy, gastrointestinal side effects, and the practical limits of this emerging therapy.

Show Notes

]]>The Medical BriefThis episode explores a new mechanistic approach to treating schizophrenia with xanomeline-trospium, which targets central muscarinic receptors to reduce psychosis without directly blocking dopamine. It also breaks down the EMERGENT trial results, includiThis episode explores a new mechanistic approach to treating schizophrenia with xanomeline-trospium, which targets central muscarinic receptors to reduce psychosis without directly blocking dopamine. It also breaks down the EMERGENT trial results, including efficacy, gastrointestinal side effects, and the practical limits of this emerging therapy. Show Notes Efficacy and safety of the muscarinic receptor agonist KarXT ... - PubMed: https://pubmed.ncbi.nlm.nih.gov/38104575/ Efficacy and Safety of Xanomeline-Trospium Chloride in ...: https://pubmed.ncbi.nlm.nih.gov/38691387/false00:05:40full<![CDATA[Prehospital Whole Blood: Promise, Pitfalls, and the SWiFT Trial]]>https://the-medical-brief-mwb6nj.jellypod.com/episodes/5269d69e-76e9-498f-9149-7c0e190fdd4d5269d69e-76e9-498f-9149-7c0e190fdd4dTue, 11 Aug 2026 14:33:23 GMT2626An air ambulance trauma trial tested whether cold-stored low titer O positive whole blood outperformed standard component therapy, and the results challenged a lot of assumptions. The episode breaks down the physiology, the SWiFT study data, and why whole blood may still have a role in longer or more remote prehospital settings.

]]>The Medical BriefAn air ambulance trauma trial tested whether cold-stored low titer O positive whole blood outperformed standard component therapy, and the results challenged a lot of assumptions. The episode breaks down the physiology, the SWiFT study data, and why wholeAn air ambulance trauma trial tested whether cold-stored low titer O positive whole blood outperformed standard component therapy, and the results challenged a lot of assumptions. The episode breaks down the physiology, the SWiFT study data, and why whole blood may still have a role in longer or more remote prehospital settings.false00:05:54full